- Title
- Consensus statement on the current pharmacological prevention and management of heart failure
- Creator
- Sindone, Andrew P.; De Pasquale, Carmine; Amerena, John; Burdeniuk, Christine; Chan, Alicia; Coats, Andrew; Hare, David L.; Macdonald, Peter; Sverdlov, Aaron; Atherton, John J.
- Relation
- Medical Journal of Australia Vol. 217, Issue 4, p. 212-217
- Publisher Link
- http://dx.doi.org/10.5694/mja2.51656
- Publisher
- John Wiley & Sons
- Resource Type
- journal article
- Date
- 2022
- Description
- Introduction: This consensus statement of Australian clinicians provides new recommendations for the pharmacological management of heart failure based on studies reported since the publication of the 2018 Australian heart failure guidelines. Main recommendations: ▪ Use of sodium–glucose cotransporter 2 (SGLT2) inhibitors to prevent hospitalisation for heart failure in type 2 diabetes mellitus can be extended to patients with multiple cardiovascular risk factors, albuminuric chronic kidney disease, or atherosclerotic cardiovascular disease. ▪ New evidence supports the use of a mineralocorticoid receptor antagonist (finerenone) to prevent heart failure in type 2 diabetes mellitus associated with albuminuric chronic kidney disease. ▪ In addition to renin angiotensin system inhibitors (angiotensin receptor neprilysin inhibitor preferred), beta blockers and mineralocorticoid receptor antagonists, an SGLT2 inhibitor (dapagliflozin or empagliflozin) is recommended in all patients with heart failure with reduced left ventricular ejection fraction (LVEF ≤ 40%) (HFrEF). Lower quality evidence supports these therapies in patients with heart failure with mildly reduced LVEF (41-49%) (HFmrEF). ▪ A soluble guanylate cyclase stimulator (vericiguat), selective cardiac myosin activator (omecamtiv mecarbil) and, if iron deficient, intravenous iron (ferric carboxymaltose) provide additional benefits in persistent HFrEF. ▪ An SGLT2 inhibitor (empagliflozin) should be considered in patients with heart failure with preserved LVEF (≥ 50%) (HFpEF). Key changes in management from this statement: This document broadens the scope of angiotensin receptor neprilysin inhibitor use in patients with HFrEF and HFmrEF. SGLT2 inhibitor use expands to become a cornerstone therapy in HFrEF, with increasing evidence to support its use in HFmrEF and HFpEF.
- Subject
- cardiomyopathies; guidelines as topic; heart failure; management; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1482087
- Identifier
- uon:50853
- Identifier
- ISSN:0025-729X
- Rights
- © 2022 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
- Language
- eng
- Full Text
- Reviewed
- Hits: 2309
- Visitors: 2323
- Downloads: 45
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 755 KB | Adobe Acrobat PDF | View Details Download |